Prognostic significance of urinary neutrophil gelatinase associated lipocalin for predicting chronic kidney disease in nonalcoholic fatty liver patients.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20180909001

Enrollment

426

Registered

2018-09-09

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease nonalcoholic fatty liver disease nonalcoholic fatty liver disease chronic kidney disease urine neutrophil gelatinase associated lipocalin (NGAL)

Interventions

GFR > 6o ml/min/1.73 m2,GFR < 6o ml/min/1.73 m2

Diagnostic,Diagnostic

no chronic kidney disease,chronic kidney disease

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: nonalcoholic fatty liver patient who was diagnosed by liver biopsy or transient elastrography

Exclusion criteria

Exclusion criteria: pregnant have cancer viral hepatitis B or C infection alcohol consumption acute kidney injury End stage renal disease

Design outcomes

Primary

Measure	Time frame
Prognostic significance of urinary neutrophil gelatinase associated lipocalin for predicting chronic 1 year urine Neutrophil gelatinase associated lipocalin (NGAL) level	—

Secondary

Measure	Time frame
urine Neutrophil gelatinase associated lipocalin (NGAL) level in each stage of chronic kidney diseas 1 year urine Neutrophil gelatinase associated lipocalin (NGAL) level	—

Countries

Thailand

Contacts

Public ContactHuttakan Navadurong

Faculty of medicine, Chulalongkorn university

huttakarn@yahoo.com0853563698

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026